[
  {
    "ts": null,
    "headline": "44th Annual J.P. Morgan Healthcare Conference",
    "summary": "44th Annual J.P. Morgan Healthcare Conference",
    "url": "https://finnhub.io/api/news?id=f93a264e104b1bb78468470d79231ad54a2201d621803017664f1535361d89c6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768344972,
      "headline": "44th Annual J.P. Morgan Healthcare Conference",
      "id": 138089996,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f93a264e104b1bb78468470d79231ad54a2201d621803017664f1535361d89c6"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and",
    "url": "https://finnhub.io/api/news?id=55427c50acf73d92a339e4634b7a6e340df09a2ca208de026695145278b06c45",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768337393,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 138089298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and",
      "url": "https://finnhub.io/api/news?id=55427c50acf73d92a339e4634b7a6e340df09a2ca208de026695145278b06c45"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly CFO: Weight-loss pill could have 20% global penetration",
    "summary": "Eli Lilly (LLY) says its weight-loss pill is on track to be approved in the US, lagging behind Novo Nordisk (NVO). Eli Lilly CFO and executive vice president Lucas Montarce sits down with Market Catalysts host Julie Hyman to outline the company's expectations for its weight-loss pill and its anticipated impact on market penetration. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=26b249544dc06fee269654e10a89f07036eeaacc9819af031065b8112895ea9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768334400,
      "headline": "Eli Lilly CFO: Weight-loss pill could have 20% global penetration",
      "id": 138091011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) says its weight-loss pill is on track to be approved in the US, lagging behind Novo Nordisk (NVO). Eli Lilly CFO and executive vice president Lucas Montarce sits down with Market Catalysts host Julie Hyman to outline the company's expectations for its weight-loss pill and its anticipated impact on market penetration. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=26b249544dc06fee269654e10a89f07036eeaacc9819af031065b8112895ea9c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
    "summary": "Eli Lilly and Company (LLY) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 5:15 PM ESTCompany ParticipantsDavid Ricks - Chairman &...",
    "url": "https://finnhub.io/api/news?id=817f3d7b37e8449f778ac2931b8eec37456049655dc5a6ceafa5747a7c62339a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768334160,
      "headline": "Eli Lilly and Company (LLY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
      "id": 138089252,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company (LLY) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 5:15 PM ESTCompany ParticipantsDavid Ricks - Chairman &...",
      "url": "https://finnhub.io/api/news?id=817f3d7b37e8449f778ac2931b8eec37456049655dc5a6ceafa5747a7c62339a"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk CEO warns of international competition headwinds, cites Lilly",
    "summary": "Investing.com -- Novo Nordisk CEO Mike Doustdar said the company faces headwinds in its international operations in 2026 as competition increases following the loss of market exclusivity in several countries.",
    "url": "https://finnhub.io/api/news?id=8a1ed8f1f794a5fda5519edbba6dbddfdc0e3bfe7d7591d227d7e94cea5b9dc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768332332,
      "headline": "Novo Nordisk CEO warns of international competition headwinds, cites Lilly",
      "id": 138091012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk CEO Mike Doustdar said the company faces headwinds in its international operations in 2026 as competition increases following the loss of market exclusivity in several countries.",
      "url": "https://finnhub.io/api/news?id=8a1ed8f1f794a5fda5519edbba6dbddfdc0e3bfe7d7591d227d7e94cea5b9dc0"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Tuesday Afternoon",
    "summary": "Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the S",
    "url": "https://finnhub.io/api/news?id=bf2b1443ae5b48f5dbb4d87a4a9040925c4b953508fd3c01891405db23c41578",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768329695,
      "headline": "Sector Update: Health Care Stocks Decline Tuesday Afternoon",
      "id": 138087367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the S",
      "url": "https://finnhub.io/api/news?id=bf2b1443ae5b48f5dbb4d87a4a9040925c4b953508fd3c01891405db23c41578"
    }
  },
  {
    "ts": null,
    "headline": "The Big Picture: Thoughts On Oil And AI 'Cross-Pollination'",
    "summary": "Avoid false market narratives in 2026: why Exxon, Chevron & COP face oil oversupply risk, while AI-driven tech stays bullish. Read my analysis here.",
    "url": "https://finnhub.io/api/news?id=dfe0b12d41ba2857dbed213a05b0926f792d188377a8ca3f4de7bc6d719ed0e7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768326722,
      "headline": "The Big Picture: Thoughts On Oil And AI 'Cross-Pollination'",
      "id": 138088752,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/497522144/image_497522144.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Avoid false market narratives in 2026: why Exxon, Chevron & COP face oil oversupply risk, while AI-driven tech stays bullish. Read my analysis here.",
      "url": "https://finnhub.io/api/news?id=dfe0b12d41ba2857dbed213a05b0926f792d188377a8ca3f4de7bc6d719ed0e7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly teams up with Nvidia on AI lab: CFO explains why",
    "summary": "Eli Lilly (LLY) is teaming up with Nvidia (NVDA) to invest in an artificial intelligence (AI) innovation lab. Eli Lilly CFO and executive vice president Lucas Montarce joins Market Catalysts host Julie Hyman to discuss how the pharmaceutical company is leveraging AI to expedite drug discovery. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=560c9be3a136405dbbe3f3d468d0b45664c930ce7c50a3905d293cff12eed654",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768324353,
      "headline": "Eli Lilly teams up with Nvidia on AI lab: CFO explains why",
      "id": 138086455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is teaming up with Nvidia (NVDA) to invest in an artificial intelligence (AI) innovation lab. Eli Lilly CFO and executive vice president Lucas Montarce joins Market Catalysts host Julie Hyman to discuss how the pharmaceutical company is leveraging AI to expedite drug discovery. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=560c9be3a136405dbbe3f3d468d0b45664c930ce7c50a3905d293cff12eed654"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Boeing Q4 Deliveries Rise; L3Harris $1 Billion Investment; JPMorgan Chase Q4 Earnings Fall",
    "summary": "The Dow Jones Industrial Average was down, the S&P 500 was roughly flat and the Nasdaq Composite was",
    "url": "https://finnhub.io/api/news?id=29d8cc6cd15b2689f9349c695afda683f577fba31176e213bff3d521a7375551",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768324042,
      "headline": "Top Midday Stories: Boeing Q4 Deliveries Rise; L3Harris $1 Billion Investment; JPMorgan Chase Q4 Earnings Fall",
      "id": 138086601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average was down, the S&P 500 was roughly flat and the Nasdaq Composite was",
      "url": "https://finnhub.io/api/news?id=29d8cc6cd15b2689f9349c695afda683f577fba31176e213bff3d521a7375551"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Retail Giant Amazon Stock Eyes Latest Buy Point",
    "summary": "Dow Jones retail giant Amazon is approaching a fresh buy point, as the stock market holds near record highs.",
    "url": "https://finnhub.io/api/news?id=3677986e67fa36743fff463850a58bdedb559ef4c93c13bbdeaf73b53fa1d579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768324017,
      "headline": "Dow Jones Retail Giant Amazon Stock Eyes Latest Buy Point",
      "id": 138086514,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Dow Jones retail giant Amazon is approaching a fresh buy point, as the stock market holds near record highs.",
      "url": "https://finnhub.io/api/news?id=3677986e67fa36743fff463850a58bdedb559ef4c93c13bbdeaf73b53fa1d579"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?",
    "summary": "Both companies now aim to win in the oral weight loss drug market.",
    "url": "https://finnhub.io/api/news?id=fc71e99f92cc944c17a9e22e4875bfc9b9cbc7f1aaba611d90536652ed5f2706",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768318500,
      "headline": "Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?",
      "id": 138086616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Both companies now aim to win in the oral weight loss drug market.",
      "url": "https://finnhub.io/api/news?id=fc71e99f92cc944c17a9e22e4875bfc9b9cbc7f1aaba611d90536652ed5f2706"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Lam Research and Ampco-Pittsburgh",
    "summary": "Microsoft headlines Zacks' Analyst Blog as strong cloud, AI, and semiconductor trends shape outlooks across tech and healthcare.",
    "url": "https://finnhub.io/api/news?id=32dd6c1ba7ad5322e5a257752ce98b3a45ce6e6fc6ed5825fe3de40da7bde77e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768318320,
      "headline": "The Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Lam Research and Ampco-Pittsburgh",
      "id": 138086508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Microsoft headlines Zacks' Analyst Blog as strong cloud, AI, and semiconductor trends shape outlooks across tech and healthcare.",
      "url": "https://finnhub.io/api/news?id=32dd6c1ba7ad5322e5a257752ce98b3a45ce6e6fc6ed5825fe3de40da7bde77e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?",
    "summary": "NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.",
    "url": "https://finnhub.io/api/news?id=ef90a57c2930eaa1147806c5c003385ea26b6862bc01e99720371fce409a4caf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768316280,
      "headline": "Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?",
      "id": 138086618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.",
      "url": "https://finnhub.io/api/news?id=ef90a57c2930eaa1147806c5c003385ea26b6862bc01e99720371fce409a4caf"
    }
  },
  {
    "ts": null,
    "headline": "Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery",
    "summary": "Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.",
    "url": "https://finnhub.io/api/news?id=f416e6c51aa734dff349ee105f949067ae902e1dc86ef8977b34801345333145",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768313700,
      "headline": "Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery",
      "id": 138084482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.",
      "url": "https://finnhub.io/api/news?id=f416e6c51aa734dff349ee105f949067ae902e1dc86ef8977b34801345333145"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics",
    "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer discussed, along with recent market rotation. When a caller asked about the stock, here’s what Cramer had to say in response: “Okay, no, look, I’m a Eli Lilly guy, okay? I’m going to stick with it. If I’m going to do Viking, I’m going […]",
    "url": "https://finnhub.io/api/news?id=37a6aea0c34cabcbfacb16e19ab25780377cc295fc7d90b24ae0b06f0c7514fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768313179,
      "headline": "Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics",
      "id": 138084483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer discussed, along with recent market rotation. When a caller asked about the stock, here’s what Cramer had to say in response: “Okay, no, look, I’m a Eli Lilly guy, okay? I’m going to stick with it. If I’m going to do Viking, I’m going […]",
      "url": "https://finnhub.io/api/news?id=37a6aea0c34cabcbfacb16e19ab25780377cc295fc7d90b24ae0b06f0c7514fe"
    }
  },
  {
    "ts": null,
    "headline": "Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?",
    "summary": "The gap may be too hard to close in the next 12 months.",
    "url": "https://finnhub.io/api/news?id=839709bee0bcfbbede0c97666994350dc057550596de186ae93af39f9c46ea1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768312920,
      "headline": "Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?",
      "id": 138084484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The gap may be too hard to close in the next 12 months.",
      "url": "https://finnhub.io/api/news?id=839709bee0bcfbbede0c97666994350dc057550596de186ae93af39f9c46ea1a"
    }
  },
  {
    "ts": null,
    "headline": "What to Expect From Eli Lilly’s Q4 2025 Earnings Report",
    "summary": "Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.",
    "url": "https://finnhub.io/api/news?id=9587fd80beff7fea7b161fc4396b2606e203898a7144a1bd00b6be7a7bf2d6a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308720,
      "headline": "What to Expect From Eli Lilly’s Q4 2025 Earnings Report",
      "id": 138086619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.",
      "url": "https://finnhub.io/api/news?id=9587fd80beff7fea7b161fc4396b2606e203898a7144a1bd00b6be7a7bf2d6a1"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
    "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
    "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308508,
      "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
      "id": 138083148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
      "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=2b7695e2beedfa3ea8c953ed19767036b271ccd1aaba133d4bb2087f5d213804",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768305180,
      "headline": "Health Care Roundup: Market Talk",
      "id": 138083149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Find insight on Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=2b7695e2beedfa3ea8c953ed19767036b271ccd1aaba133d4bb2087f5d213804"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises on $1 Billion AI Bet With Nvidia",
    "summary": "Nvidia Pushes Deeper Into Health Care With Major Eli Lilly Partnership",
    "url": "https://finnhub.io/api/news?id=6728de73fb4c347ef7a56fc676c48441f4981dfd7a89ca00f475feb7c7322b37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768303630,
      "headline": "Eli Lilly Stock Rises on $1 Billion AI Bet With Nvidia",
      "id": 138082974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nvidia Pushes Deeper Into Health Care With Major Eli Lilly Partnership",
      "url": "https://finnhub.io/api/news?id=6728de73fb4c347ef7a56fc676c48441f4981dfd7a89ca00f475feb7c7322b37"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
    "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
    "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768299840,
      "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
      "id": 138083151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
      "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook",
    "summary": "Eli Lilly chairman and CEO David Ricks joins 'Squawk on the Street' to discuss the path to becoming a trillion dollar company, launch of its obesity pill, new innovation at the company, drug pipeline outlook, and more.",
    "url": "https://finnhub.io/api/news?id=901f464bc2cb8026d261df285c8540fea3c39bb67f698e9ba49eaca6a29db54c",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768298600,
      "headline": "Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook",
      "id": 138085716,
      "image": "https://image.cnbcfm.com/api/v1/image/108251723-17683158841768315881-43476061312-1080pnbcnews.jpg?v=1768315883&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Eli Lilly chairman and CEO David Ricks joins 'Squawk on the Street' to discuss the path to becoming a trillion dollar company, launch of its obesity pill, new innovation at the company, drug pipeline outlook, and more.",
      "url": "https://finnhub.io/api/news?id=901f464bc2cb8026d261df285c8540fea3c39bb67f698e9ba49eaca6a29db54c"
    }
  },
  {
    "ts": null,
    "headline": "The market's Powell reaction, JPMorgan earnings, Siri's AI upgrade and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=9c91f58a0b0741c81239407b18bf4ff90050916fdd98f3391011fd11529f06f3",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768291242,
      "headline": "The market's Powell reaction, JPMorgan earnings, Siri's AI upgrade and more in Morning Squawk",
      "id": 138085582,
      "image": "https://image.cnbcfm.com/api/v1/image/108214888-17610696602025-10-21t171855z_1126286995_rc2dghapsvej_rtrmadp_0_jpmorgan-new-york.jpeg?v=1761069721&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=9c91f58a0b0741c81239407b18bf4ff90050916fdd98f3391011fd11529f06f3"
    }
  }
]